by thyroid disorders. This report describes a case of Graves hyperthyroidism after 8 years of tremelimumab therapy. We speculate a causal relationship between tremelimumab therapy and the development of Graves disease, and highlight the importance
Earn H. Gan, Anna L. Mitchell, Ruth Plummer, Simon Pearce, and Petros Perros
Elena Sabini, Ilaria Ionni, Roberto Rocchi, Paolo Vitti, Claudio Marcocci, and Michele Marinò
deterioration of Graves’ orbitopathy in patients with Graves’ hyperthyroidism. A similar release of autoantigens may occur at the eye level resulting in the development of Graves’ orbitopathy. What Does This Case Report Add? To our knowledge
Alan Chun Hong Lee and George J. Kahaly
Introduction Graves’ disease (GD) accounts for 75% of hyperthyroidism in iodine-replete geographical areas. Approximately one-fifth of GD patients develop Graves’ orbitopathy (GO), which is the most common extrathyroidal manifestation of GD
Allan Carlé, Nils Knudsen, Torben Jørgensen, Bettina Thuesen, Jesper Karmisholt, Stine Linding Andersen, and Inge Bülow Pedersen
studies [ 5 ], have shown a lower risk during pregnancy of developing autoimmune thyroid disease such as Graves’ hyperthyroidism and autoimmune hypothyroidism. Due to the so called “rebound phenomenon,” the risk of autoimmune thyroid disease after delivery
Meihua Jin, Ahreum Jang, Chae A Kim, Tae Young Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, and Won Gu Kim
Introduction Graves’ hyperthyroidism is an autoimmune disease in which thyrotropin (thyroid-stimulating hormone (TSH)) receptor antibody (TRAb) stimulates thyroid follicular cells, resulting in thyrotoxicosis and enlargement of the thyroid
George J. Kahaly, Luigi Bartalena, Lazlo Hegedüs, Laurence Leenhardt, Kris Poppe, and Simon H. Pearce
hyperthyroidism is 1.2–1.6, 0.5–0.6 overt and 0.7–1.0% subclinical [ 1 , 5 ]. The most frequent causes are Graves’ disease (GD) and toxic nodular goiter. GD is the most prevalent cause of hyperthyroidism in iodine-replete geographical areas, with 20–30 annual
Roberto Negro, Laszlo Hegedüs, Roberto Attanasio, Enrico Papini, and Kristian H. Winther
. 2017 Oct ; 24 ( 5 ): 348 – 55 . 10.1097/MED.0000000000000356 28639965 1752-296X 19 Kahaly GJ , Riedl M , König J , Diana T , Schomburg L . Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism
Tetsuya Mizokami, Katsuhiko Hamada, Tetsushi Maruta, Kiichiro Higashi, and Junichi Tajiri
What Is Known about This Topic? • Anterior neck pain and fever, caused by radiation thyroiditis, is a rare occurrence after 131 I therapy for Graves' hyperthyroidism. In addition, the ultrasonographic findings have not been well described
J Karmisholt, S L Andersen, I Bulow-Pedersen, A Krejbjerg, B Nygaard, and A Carlé
Introduction Graves’ hyperthyroidism (GH) is an autoimmune disease mainly affecting the thyroid gland ( 1 , 2 ). The disease is usually transient with remission occurring within a period of 1–2 years after treatment with anti-thyroid drugs
Shakeel Kautbally, Orsalia Alexopoulou, Chantal Daumerie, François Jamar, Michel Mourad, and Dominique Maiter
Group 1996: Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009;94:3700–3707. 10.1210/jc.2009-0747 5 Laurberg P, Wallin G, Tallstedt L, Abraham
